Hepatocellular Carcinoma

News Hepatocellular Carcinoma

• Genetic Variant Linked to Development of Liver Cancer in Hepatitis C Virus Carriers

  A genome-wide study by researchers at the RIKEN Center for Genomic Medicine, Hiroshima University Hospital and Sapporo-Kosei General Hospital has identified a genetic variant associated with the development of liver cancer in chronic hepatitis C virus carriers. The findings are based on a study of 3 more

• Livatag follow up demonstrates significant survival increase in advanced hepatocellular carcinoma patients

  BioAlliance Pharma SA announced the update of its preliminary positive survival data with Livatag® (doxorubicin Transdrug™). Livatag® is a treatment presented in nanoparticles able to deliver doxorubicin in chemoresistant cells. Livatag® was granted an orphan drug status in Europe and in the United more

• Vaxon Biotech successfully completes its Phase I/II trial of Vx-001 cancer vaccine

  Vaxon Biotech announced the successful conclusion of the Phase I/II trial of its Vx-001 therapeutic cancer vaccine. As a result, Vaxon is pursuing the clinical development of Vx-001 by launching a pivotal phase III trial in non-small cell lung cancer (NSCLC) in 2010, and in hepatocellular carcinoma more

White papers Hepatocellular Carcinoma

• Trichostatin A Treatment of Cells Transfected with FuGENE® HD Transfection Reagent
  

  Treatment of eukaryotic cells with trichostatin A (TSA) - a broad-spectrum inhibitor of histone deacetylation - is frequently used in studies of epigenetic regulation of gene expression. To be able to investigate the effects of TSA on promoter activity in reporter gene assays it is necessary to secure high transfection efficiency and low toxicity of the transfection reagent. In this study we tested transfection efficiency and toxicity of FuGENE® HD Transfection Reagent in experiments with hepatoma cell line HepG2. We also established a protocol for TSA treatment that guarantees high cell survival and sufficient TSA effect more

Publications Hepatocellular Carcinoma

• A comparison of efficacy and safety of 2‐year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match–control study

  Abstract There are limited data comparing the clinical outcomes between telbivudine and entecavir. We consecutively enrolled 115 telbivudine‐naive and 115 entecavir‐naive chronic hepatitis B patients, who were matched for age, sex, hepatitis B e antigen (HBeAg) status and cirrhosis, and treated more

• Prohibitin‐2 promotes hepatocellular carcinoma malignancy progression in hypoxia based on a label‐free quantitative proteomics strategy

  Abstract The rapid growth of hepatocellular carcinoma (HCC) leading to tumor hypoxia is a common pathological phenomenon. Meanwhile, tumor hypoxia can promote a change in the biological properties of tumor cells. It may enhance the survival of tumor cells under stress conditions, resulting in r more

• 14-3-3ε Boosts Bleomycin-induced DNA Damage Response by Inhibiting the Drug-resistant Activity of MVP

  Major vault protein (MVP) is the predominant constituent of the vault particle, the largest known ribonuclear protein complex. Although emerging evidence have been establishing the links between MVP (vault) and multidrug resistance (MDR), little is known regarding exactly how the MDR activity of MVP more

Market studies Hepatocellular Carcinoma

• Hepatocellular Carcinoma – Pipeline Review, H1 2012

  Introduction Global Markets Direct’s, 'Hepatocellular Carcinoma - Pipeline Review, H1 2012', provides an overview of the Hepatocellular Carcinoma therapeutic pipeline. This report provides information on the therapeutic development for Hepatocellular Carcinoma, complete with latest updates, and spe more

• Hepatocellular Carcinoma Global Clinical Trials Review, H1, 2012

  Introduction GlobalData's clinical trial report, “Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2011" provides data on the Hepatocellular Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatocellular Carcinoma. more

• Metastatic Hepatocellular Carcinoma (HCC) – Pipeline Review, H1 2012

  Introduction Global Markets Direct’s, 'Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2012', provides an overview of the Metastatic Hepatocellular Carcinoma (HCC) therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Hepatocellular Ca more

Websites Hepatocellular Carcinoma